AdvaMed Announces Formation of Medical Imaging Division

World’s largest medical imaging companies join world’s largest medtech association

WASHINGTON, D.C.,  – Today, AdvaMed, the Medtech Association, announced the establishment of a new Medical Imaging Technology division focused on advocating on behalf of large and small companies for the essential role of medical imaging technology, radiopharmaceuticals, contrast media, and focused ultrasound devices in our nation’s health care system. Leading medical imaging companies – such as Bayer, Fujifilm Sonosite, GE HealthCare, Hologic, Philips, and Siemens Healthineers – have formally established AdvaMed as the new home for advocacy on behalf of medical imaging companies, which previously sat within the Medical Imaging & Technology Alliance (MITA), a division of the  National Electrical Manufacturers Association (NEMA). 

AdvaMed President and CEO Scott Whitaker said : “This new division is a big step forward not merely for the medical imaging sector, but for AdvaMed and the entire medtech industry. Never before have medical technologies been so connected and interdependent as they are today—and it’s really only the beginning. From traditional medical devices to digital health tech to AI and medical imaging, the opportunity to unify the industry and advance policy solutions for the health care system has never been better. No trade organization is better prepared than AdvaMed to represent the entire medtech industry and take on these advocacy challenges so that our members can continue focusing on what they do best—meeting the needs of the patients they serve. 

“Finally, the timing of Peter Arduini’s election as our new Chair couldn’t be better. His leadership of GE HealthCare, a global leader in medical imaging, pharmaceutical diagnostics and digital solutions, will provide strategic insight and direction to AdvaMed as we work to ensure an aligned and inclusive focus across companies in every sector of medtech.”

Peter J. Arduini, President and CEO of GE HealthCare and newly elected Chair of the AdvaMed Board of Directors, said of the new division : “We are in a new era in which providers and patients rely on medical imaging and digital solutions for critical insights across the entire care pathway from screening, diagnosis, monitoring, and therapy delivery, as well as research and discovery.  As Chair, I look forward to working alongside Scott and my colleagues from across the industry to establish AdvaMed’s new imaging division and ensure it is aligned and integrated to our overall goals of the med tech industry.”

Patrick Hope served as executive director of MITA since 2015 and will now serve as executive director of the new Medical Imaging Technology division at AdvaMed. Hope said : “The future is brighter than ever for the medical imaging companies we served at MITA. Our new home at AdvaMed makes perfect sense: For the first time, we will be surrounded by a team, infrastructure, and resources focused entirely on the patients our companies serve. We will be surrounded by and working directly with experts in medtech policy at the state, national, and global levels. I am 100 percent confident that our companies will see more value in our work together under the AdvaMed umbrella than ever before.

Imaging plays a critical role in our health care system, from diagnosis to treatment:  

  • In the U.S., a medical image is taken every 3 seconds
  • Imaging makes up approximately 80 percent of AI technology cleared by FDA

As is the case with AdvaMed’s Accel, Dx, and Digital Health Tech divisions, AdvaMed’s new Medical Imaging Technology division will be led by a Board of Directors comprised of executives from its imaging company members. The new division will be led within AdvaMed by Patrick Hope, former Executive Director of the Medical Imaging Technology Alliance (MITA). Mr. Hope and Peter Weems, who led MITA’s government affairs and policy strategy, as well as other staff, will round out the division’s staffing needs at AdvaMed going forward.

This division’s creation comes on the heels of  AdvaMed’s announcement last month that it had established a Digital Health division. The recent creation of these two divisions “further demonstrates that AdvaMed is well positioned to lead the entire medtech industry on the advocacy front,” Whitaker said.

In January, AdvaMed will unveil a refreshed version of its “ Medical Innovation Agenda for the 118 th  Congress ,” a list of policy and legislative priorities critical to patient care that will include a new set of priorities for the medical imaging sector.

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.

GLS Joins Georgia Partners in Calling for Federal PBM Reform

December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.

GLS’ President and CEO, Maria Thacker Goethe in December's issue of Georgia Trend

December 4, 2025
Georgia Life Sciences’ CEO, Maria Thacker Goethe shares her perspective on the value of Georgia’s research universities in this month’s issue of Georgia Trend. “Georgia research institutions have felt a very significant impact from the federal rollbacks, specifically in NIH and NSF funding. Thacker Goethe’s message about the impact of research cuts is simple: Disruption shatters the foundational trust researchers have in grant continuity….” To read the full article, click here .
MORE POSTS